Current News

Walbrook PR announces its appointment as Financial Public Relations advisor to TyraTech Inc (AIM: TYR and TYRU), the natural life sciences Company focussed on effective and safe insect and parasite control technologies.

Tyratech Inc (AIM: TYR and TYRU), was established in 2004 to utilise novel technology, originally developed by the Vanderbilt-Ingram Cancer Center, to fill the unmet and increasing global need for effective, safe and natural pesticide technologies. TyraTech, Inc. made its Initial Public Offering on the London Alternative Investment Market in 2007.

Over the last 12 months the Company has progressed from the development of its platform and products into its commercialisation phase. The Company's product pipeline now includes more than 15 products at various stages of development with eight products ready for commercialisation across the insect control, human and animal health markets. The Company has also developed commercial partnerships and distribution channels, particularly in the US and EU.

On the 18th March 2013, TyraTech announced it had conditionally raised £3m through the Placing and Subscription of New Common Shares at an Issue Price of 5 pence per share, before expenses, to fund the commercialisation of registered products in North America and the European Union; apply for additional product registrations in the Company's key markets and geographies; finish the late pipeline development of products close to registration and commercialisation; develop and expand the Company's channels to market by signing up with additional retail and other commercial/distribution partners; and support general corporate purposes. For more information, please visit: http://www.tyratech.com

Walbrook will advise TyraTech Inc on its strategic financial communications across the financial media, sell-side equity research analysts and growth company investor groups within the UK.

Paul Cornelius, Director of Walbrook PR, said: "We are delighted to have been selected by TyraTech to help build the Company's profile within the UK capital markets. The opportunity for a fully funded TyraTech at this time is particularly exciting as it moves to commercialise its products across the global and multi-billion dollar human and animal healthcare markets. We are therefore particularly excited to be involved in communicating the Company's developments at this stage of the Company's development."